Propranolol for Severe Infantile Hemangiomas: Follow-Up Report

OBJECTIVE: Infantile hemangiomas (IHs) are the most-common soft-tissue tumors of infancy. We report the use of propranolol to control the growth phase of IHs. METHODS: Propranolol was given to 32 children (21 girls; mean age at onset of treatment: 4.2 months) after clinical and ultrasound evaluations. After electrocardiographic and echocardiographic evaluations, propranolol was administered with a starting dose of 2 to 3 mg/kg per day, given in 2 or 3 divided doses. Blood pressure and heart rate were monitored during the first 6 hours of treatment. In the absence of side effects, treatment was continued at home and the child was reevaluated after 10 days of treatment and then every month. Ultrasound measurements were performed after 60 days of treatment. RESULTS: Immediate effects on color and growth were noted in all cases and were especially dramatic in cases of dyspnea, hemodynamic compromise, or palpebral occlusion. In ulcerated IHs, complete healing occurred in <2 months. Objective clinical and ultrasound evidence of longer-term regression was seen in 2 months. Systemic corticosteroid treatment could be stopped within a few weeks. Treatment was administered for a mean total duration of 6.1 months. Relapses were mild and responded to retreatment. Side effects were limited and mild. One patient discontinued treatment because of wheezing. CONCLUSION: Propranolol administered orally at 2 to 3 mg/kg per day has a consistent, rapid, therapeutic effect, leading to considerable shortening of the natural course of IHs, with good clinical tolerance.

[1]  E. Boscolo,et al.  Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. , 2008, The Journal of clinical investigation.

[2]  F. Boralevi,et al.  Propranolol for severe hemangiomas of infancy. , 2008, The New England journal of medicine.

[3]  G. Gurtner,et al.  Hypoxia-Induced Mediators of Stem/Progenitor Cell Trafficking Are Increased in Children With Hemangioma , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[4]  M. Chiariello,et al.  Ischemic Neoangiogenesis Enhanced by &bgr;2-Adrenergic Receptor Overexpression: A Novel Role for the Endothelial Adrenergic System , 2005, Circulation research.

[5]  M. Chiariello,et al.  Ischemic Neoangiogenesis Enhanced by β2-Adrenergic Receptor Overexpression , 2005 .

[6]  D. Siegel,et al.  Infantile Hemangiomas: Current Knowledge, Future Directions. Proceedings of a Research Workshop on Infantile Hemangiomas , 2005, Pediatric dermatology.

[7]  C. Simopoulos,et al.  The HIF‐2&agr;/VEGF pathway activation in cutaneous capillary haemangiomas , 2005 .

[8]  B. Hainque,et al.  Low incidence of cardiac events with beta-blocking therapy in children with long QT syndrome. , 2004, European heart journal.

[9]  N. Sikka,et al.  Are 1-2 tablets dangerous? Beta-blocker exposure in toddlers. , 2004, The Journal of emergency medicine.

[10]  A. Picard,et al.  Traitement par vincristine des hémangiomes graves du nourrisson , 2004 .

[11]  I. Frieden,et al.  Hemangiomas of infancy. , 2003, Journal of the American Academy of Dermatology.

[12]  Karen Kilian,et al.  Hypertension in Neonates: Causes and Treatments , 2003, The Journal of perinatal & neonatal nursing.

[13]  S. K. Sommers Smith,et al.  Beta blockade induces apoptosis in cultured capillary endothelial cells , 2002, In Vitro Cellular & Developmental Biology - Animal.

[14]  N. Grenier,et al.  [Color Doppler sonography of superficial capillary hemangiomas]. , 2001, Journal de radiologie.

[15]  A. Fleischer,et al.  Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. , 2001, Archives of dermatology.

[16]  J. Mulliken,et al.  Clonality and altered behavior of endothelial cells from hemangiomas. , 2001, The Journal of clinical investigation.

[17]  C. Bucana,et al.  Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN-beta. , 1999, International journal of oncology.

[18]  J. Haimowitz Guidelines of care: hemangiomas of infancy. , 1998, Journal of the American Academy of Dermatology.

[19]  J. Mulliken,et al.  Increased Apoptosis Coincides with Onset of Involution in Infantile Hemangioma , 1998, Microcirculation.

[20]  I. Frieden,et al.  Growing Up With a Facial Hemangioma: Parent and Child Coping and Adaptation , 1998, Pediatrics.

[21]  H. Lee,et al.  cAMP‐dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation , 1997, Journal of cellular biochemistry.

[22]  O. Enjolras,et al.  Superficial Hemangiomas: Associations and Management , 1997, Pediatric dermatology.

[23]  B. Smoller,et al.  Proliferation and apoptosis within juvenile capillary hemangiomas. , 1996, The American Journal of dermatopathology.

[24]  J. Mulliken,et al.  Interferon alfa‐2a therapy for life‐threatening hemangiomas of infancy , 1992, The New England journal of medicine.

[25]  M. Riché,et al.  Management of alarming hemangiomas in infancy: a review of 25 cases. , 1990, Pediatrics.

[26]  S. Seiff,et al.  Central retinal artery occlusion associated with periocular corticosteroid injection for juvenile hemangioma. , 1986, Ophthalmic surgery.

[27]  A. Margileth,et al.  Cutaneous hemangiomas in children. Diagnosis and conservative management. , 1965, JAMA.

[28]  K. Verhoeckx,et al.  Beta-adrenergic receptor agonists induce the release of granulocyte chemotactic protein-2, oncostatin M, and vascular endothelial growth factor from macrophages. , 2006, International immunopharmacology.

[29]  K. Shyu,et al.  Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart. , 2005, Journal of biomedical science.

[30]  A. Picard,et al.  [Vincristine treatment for function- and life-threatening infantile hemangioma]. , 2004, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[31]  F. ki,et al.  Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review. , 1998 .

[32]  E. Roubaud,et al.  [Immature cutaneous hemangiomas. Epidemiologic study of 351 cases]. , 1985, Annales de dermatologie et de venereologie.

[33]  J. Maleville,et al.  Hémangiomes cutanés immatures. Etude épidémiologique de 351 cas. , 1985 .